JIR
VRTX icon

James Investment Research’s Vertex Pharmaceuticals VRTX Stock Holding History

James Investment Research’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-39
Closed -$12K – 540
2023
Q1 		$12K Hold
39
– – ﹤0.01% 471
2022
Q4 		$11K Sell
39
-168
-81% -$51.2K ﹤0.01% 474
2022
Q3 		$60K Buy
207
+76
+58% +$21.9K 0.01% 347
2022
Q2 		$37K Buy
+131
New +$35.1K 0.01% 373

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

James Investment Research's VRTX Position: Q2 2023 in Review

James Investment Research sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 39 shares — an estimated $12K sold.

James Investment Research first reported a position in VRTX in Q2 2022 and held it in 4 quarters. The position peaked at $60K in Q3 2022. 1,285 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

  • James Investment Research reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • James Investment Research sold 39 Vertex Pharmaceuticals shares in Q2 2023, an estimated $12K.
  • James Investment Research first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 4 quarters.
  • James Investment Research's Vertex Pharmaceuticals position peaked at $60K in Q3 2022.
  • 1,285 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on James Investment Research's 13F filing for Q2 2023, filed 7 Aug 2023.